According to research, the lot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75. The research as presented at the American College of Cardiology's 62nd Annual Scientific Session.
Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing between 60,000 and 100,000 Americans each year. The most common cause of death is progressive failure of the heart's right ventricle, which sends blood to the lungs to pick up oxygen. Right ventricle failure leads to hemodynamic collapse, which means blood no longer circulates properly. Blood pressure suddenly drops or disappears altogether, and the risk of death is high.
Pulmonary Embolism
Pulmonary embolism (PE) is a complication that results from a block in the main artery supplying the lungs
Advertisement
Heparin is the current standard therapy for most patients, including a subgroup of patients that is said to have submassive or intermediate-risk pulmonary embolism: that is, they have normal blood pressure but dysfunction of the heart's right ventricle, which can be seen on an echocardiogram or CT scan. Blood tests also can help to identify these patients.
The Pulmonary Embolism Thrombolysis Study (PEITHO) tested the addition of a clot-busting (thrombolytic) drug, tenecteplase, to standard treatment with heparin. Tenecteplase dissolves blood clots rapidly but carries a known risk of bleeding in the brain. The double-blind study included 1,006 patients in 13 countries. They were randomized to heparin plus placebo or heparin plus tenecteplase.
![Pulmonary Embolism and Deep Vein Thrombosis]( "Pulmonary Embolism and Deep Vein Thrombosis")
Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of the legs. Pulmonary embolism (PE) occurs when these clots break away and block the pulmonary artery.
The combined primary endpoint was death from any cause or circulatory system (hemodynamic) collapse after seven days. Hemodynamic collapse was defined as at least one of the following: needing CPR due to a loss of blood pressure; systolic blood pressure of less than 90 mm Hg or a drop of more than 40 mm Hg for at least 15 minutes; or the need for drugs called catecholamines, which boost circulation.
The primary endpoint was reduced by 56 percent in patients treated with tenecteplase and heparin, compared with the heparin-only group.
"In patients with intermediate-risk pulmonary embolism, thrombolytic treatment significantly reduced the primary endpoint," said Stavros Konstantinides, MD, PhD, professor for clinical trials at the Center for Thrombosis and Hemostasis, University of Mainz, Germany, and the study's co-principal investigator. "Overall, the study strongly supports the concept that risk stratification of patients makes sense and that these patients need something to prevent deterioration."
There was a significant reduction in hemodynamic collapse: it occurred in 1.6 percent of patients receiving tenecteplase versus 5 percent receiving placebo. Actual death rates were low and not significantly different between groups: 1.2 percent in the tenecteplase group versus 1.8 percent in the placebo group.
Major bleeding was significantly increased with tenecteplase: 6.3 vs. 1.5 percent in the placebo group.There were 10 hemorrhagic strokes in the tenecteplase group and one in the placebo group.
"This is more or less the rate that we have seen in previous thrombolytic trials," Dr. Konstantinides said."Patients who were less than 75 years old had most of the benefit and a tendency toward fewer hemorrhagic strokes. Our future priorities are now to refine our risk stratification concept even further, to better identify those patients who will benefit most with less risk of bleeding. Also, the dose of the drug that we used could be lowered in older patients, and alternative methods of delivering thrombolytics could be explored."
Source: Eurekalert
Pulmonary Embolism and Deep Vein Thrombosis
Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of the legs. Pulmonary embolism (PE) occurs when these clots break away and block the pulmonary artery.
Advertisement
The combined primary endpoint was death from any cause or circulatory system (hemodynamic) collapse after seven days. Hemodynamic collapse was defined as at least one of the following: needing CPR due to a loss of blood pressure; systolic blood pressure of less than 90 mm Hg or a drop of more than 40 mm Hg for at least 15 minutes; or the need for drugs called catecholamines, which boost circulation.
The primary endpoint was reduced by 56 percent in patients treated with tenecteplase and heparin, compared with the heparin-only group.
"In patients with intermediate-risk pulmonary embolism, thrombolytic treatment significantly reduced the primary endpoint," said Stavros Konstantinides, MD, PhD, professor for clinical trials at the Center for Thrombosis and Hemostasis, University of Mainz, Germany, and the study's co-principal investigator. "Overall, the study strongly supports the concept that risk stratification of patients makes sense and that these patients need something to prevent deterioration."
There was a significant reduction in hemodynamic collapse: it occurred in 1.6 percent of patients receiving tenecteplase versus 5 percent receiving placebo. Actual death rates were low and not significantly different between groups: 1.2 percent in the tenecteplase group versus 1.8 percent in the placebo group.
Major bleeding was significantly increased with tenecteplase: 6.3 vs. 1.5 percent in the placebo group.There were 10 hemorrhagic strokes in the tenecteplase group and one in the placebo group.
"This is more or less the rate that we have seen in previous thrombolytic trials," Dr. Konstantinides said."Patients who were less than 75 years old had most of the benefit and a tendency toward fewer hemorrhagic strokes. Our future priorities are now to refine our risk stratification concept even further, to better identify those patients who will benefit most with less risk of bleeding. Also, the dose of the drug that we used could be lowered in older patients, and alternative methods of delivering thrombolytics could be explored."
Source: Eurekalert
Deep Vein Thrombosis
A blood clot (thrombus) in the deep venous system of the leg leads to deep vein thrombosis (DVT). DVT is a major cause of morbidity and mortality.
Advertisement
 Deep Vein Thrombosis and FlyingWHO sponsored Research Into Global Hazards of Travel (WRIGHT) Project has discovered that the DVT risks approximately doubles after a long-distance flight. | Advertisement
|
Advertisement
Recommended Readings
Latest General Health News
Seeking internet help for an incomplete antibiotic course resulted in kidney stone formation and urinary tract infection in a young woman.
The Brain Care Score is a tool to evaluate brain health and reduce the risk of brain disorders including dementia and stroke.
Swine influenza A viruses, including subtypes H1N1, H1N2, and H3N2, are prominent among pigs and sporadically transmit to humans.
The microorganism "is a newly identified potential disease-causing agent, possibly originating from or evolving within the dog's microbiome."
Flavanol naturally present in red wine can compromise the proper metabolism of alcohol and lead to a headache.